A connection between the body clock and abnormalities in metabolism and diabetes has been suggested in new research by an international team involving the University of Oxford, the Wellcome Trust Sanger Institute and the MRC Epidemiology Unit in Cambridge. Professor Mark McCarthy took part in the study.
Clinical trials of a new malaria vaccine have shown it provides both infants and young children with substantial protection against malaria. Dr Philip Bejon led this study.
The use of insecticide-treated bed nets (ITNs) to protect children from malaria has risen six-fold in the past seven years, according to research carried out by the Kenya Unit of the Centre for Tropical Medicine. Dr Abdisalan Noor and Professor Bob Snow participated in the study.
Cells involved in the body’s immune response to cancer are also implicated in influenza infection and could be targeted in new flu vaccination strategies, scientists at Oxford University have discovered. Professor Vincenzo Cerundolo took part in the study.
The first gene that is associated with a common childhood language disorder, known as specific language impairment (SLI), has been identified by researchers at the Wellcome Trust Centre for Human Genetics, University of Oxford. Dr Simon Fisher let the research.
Researchers from the Wellcome Trust Centre for Human Genetics (WTCHG) at the University of Oxford today announce a major new study into the genetics of major depression in a population of women in China. The five-year project is funded by a £1.4 million grant from the Wellcome Trust. One of the largest studies into depression ever carried out in China, the project is collaboration between the ...
In its latest study, researchers at University of Oxford examined the link between a sequence of DNA and reading ability in a sample of 6,000 seven to nine-year old children taking part in a major long-term study known as the Avon Longitudinal Study of Parents and Children (ALSPAC). Dr Silvia Paracchini took part in the study.
The world's leading candidate for a tuberculosis vaccine, developed at Oxford University, is to move into the next stage of development. Dr Helen McShane leads this project.
Cancer Research UK has awarded the University of Oxford’s Clinical BioManufacturing Facility (CBF) its first commercial process development contract for the production of an adenovirus vector.
Dr Andrew Roddam, from the Cancer Epidemiology Unit, worked with an international team of researchers who found that men with higher levels of IGF-1 were more likely to go on to develop prostate cancer than those with lower levels of the protein.
If you have news or events that you would like to be added to this website, please email us details. If possible, please include a picture and links to further information.